Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma

Annals of Oncology

Volumn 22, Issue 2, 2011, Pages 390-396

  Wang, Z Y ^a   Li, Y X ^a   Wang, H ^a   Wang, W H ^a   Jin, J ^a   Liu, Y P ^a   Song, Y W ^a   Wang, S L ^a   Liu, X F ^a   Yu, Z H ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Geriatric malignancy; NK T cell lymphoma; Prognosis; Radiotherapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HEPATITIS B; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; ISCHEMIC HEART DISEASE; LIVER FAILURE; LUNG INFECTION; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NK T CELL LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 79251541775     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq347     Document Type: Article

References (47)

1. Li YX, Yao B, Jin J et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol 2006; 24: 181-189.
2. Huang MJ, Jiang Y, Liu WP et al. Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma, nasal-type in the upper aerodigestive tract. Int J Radiat Oncol Biol Phys 2008; 70: 166-174.
3. Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004; 103: 216-221.
4. Li CC, Tien HF, Tang JL et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004; 100: 366-375.
5. Barrionuevo C, Zaharia M, Martinez MT et al. Extranodal NK/T-cell lymphoma, nasal type: study of clinicopathologic and prognosis factors in a series of 78 cases from Peru. Appl Immunohistochem Mol Morphol 2007; 15(1): 38-44.
6. Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-4130.
7. Bossard C, Belhadj K, Reyes F et al. Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 2007; 109: 2183-2189.
8. Kim GE, Lee SW, Chang SK et al. Combined chemotherapy and radiation versus radiation alone in the management of localized angiocentric lymphoma of the head and neck. Radiother Oncol 2001; 61: 261-269.
9. Kim TM, Lee SY, Jeon YK et al. Clinical heterogeneity of extranodal NK/T-cell lymphoma, nasal type: a national survey of the Korean Cancer Study Group. Ann Oncol 2008; 19(8): 1477-1484.
10. Au WY, Weisenburger DD, Intragumtornchai T et al. Clinical differences between nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International Peripheral T-cell Lymphoma Project. Blood 2009; 113: 3931-3937.
11. Kim K, Chie EK, Kim CW et al. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 2005; 35: 1-5.
12. Li YX, Coucke PA, Li JY et al. Primary non-Hodgkin's lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy. Cancer 1998; 83: 449-456.
13. Li YX, Fang H, Liu QF et al. Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring. Blood 2008; 112: 3057-3064.
14. Li YX, Liu QF, Fang H et al. Variable clinical presentations of nasal and Waldeyer ring natural killer/T-cell lymphoma. Clin Cancer Res 2009; 15: 2905-2912.
15. Yang Y, Zhang YJ, Lin XB et al. Role of radiotherapy in the treatment of patients with early stage extranodal nasal-type NK/T-cell lymphoma and analysis of prognostic factors. Chin J Radiat Oncol 2009; 18: 285-289.
16. Aviles A, Diaz NR, Neri N et al. Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000; 22(4): 215-220.
17. Cheung MM, Chan JK, Lau WH et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54(1): 182-190.
18. Wang ZY, Li YX, Wang WH et al. Primary radiotherapy showed favorable outcome in treating extranodal nasal-type NK/T-cell lymphoma in children and adolescents. Blood 2009; 114: 4771-4776.
19. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
20. The Non-Hodgkin's Lymphoma Classification Project: effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 1997; 8: 973-978.
21. Thieblemont C, Coiffier B. Lymphoma in older patients. J Clin Oncol 2007; 25: 1916-1923.
22. Chan JKC, Quintanilla-Martinez L, Ferry JA et al. Extranodal NK/T-cell lymphoma, nasal type. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds), World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press 2008; 285-288.
23. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-1253.
24. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
25. Bertini M, Boccomini C, Calvi R. The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). Clin Lymphoma 2001; 1: 278-284.
26. Vose JM, Armitage JO, Weisenburger DD et al. The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1988; 6: 1838-1844.
27. van Spronsen DJ, Janssen-Heijnen ML, Breed WP et al. Prevalence of comorbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol 1999; 78: 315-319.
28. Engert A, Ballova V, Haverkamp H et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23: 5052-5060.
29. Klimm B, Eich HT, Haverkamp H et al. Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma: an analysis from German Hodgkin Study Group. Ann Oncol 2007; 18: 357-363.
30. Shayne M, Culakova E, Poniewierski MS et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer 2007; 110: 1611-1620.
31. Extermann M, Aapro M, Bernabei R et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241-252.
32. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25: 1824-1831.
33. Smith JT, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelines. J Clin Oncol 2006; 24: 3187-3205.
34. Lichtman SM. Chemotherapy in the elderly. Semin Oncol 2004; 31: 160-174.
35. Pasipanodya JG, Miller TL, Vecino M et al. Pulmonary impairment after tuberculosis. Chest 2007; 131: 1817-1824.
36. Aapro MS, Cameron DA, Pettengell R et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006; 42: 2433-2453.
37. You JY, Chi KH, Yang MH et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: a single institute survey in Taiwan. Ann Oncol 2004; 15: 618-625.
38. Kim BS, Kim TY, Kim CW et al. Therapeutic outcome of extranodal T/NK-cell lymphoma initially treated with chemotherapy. Result of chemotherapy in T/NKcell lymphoma. Acta Oncol 2003; 42: 779-783.
39. Ma HH, Qian LT, Pan HF et al. Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma. Med Oncol. DOI 10.1007a/s12032-009-9288-7.
40. Aikemu W, Wang RZ, Li PD. A clinical study of 57 patients with extranodal natural killer/T-cell lymphoma, nasal-type. J Xinjiang Med Univ 2008; 31: 1507-1509.
41. Yamaguchi M, Tobinai K, Oguchi M et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol 2009; 27: 5594-5600.
42. Kim SJ, Kim K, Kim BS et al. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-cell lymphoma: consortium for improving survival of lymphoma study. J Clin Oncol 2009; 27: 6027-6032.
43. Repetto L, Venturino A, Vercelli M et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer 1998; 82: 760-765.
44. Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol 2007; 25: 1936-1944.
45. Serrano-Olvera A, Gerson R. Age associated survival rate in non-small cell lung cancer. Gac Med Mex 2009; 145: 27-35.
46. Gnerlich JL, Deshpande AD, Jeffe DB et al. Elevated breast cancer mortality in women younger than age 40 years compared with older women is attributed to poorer survival in early-stage disease. J Am Coll Surg 2009; 208: 341-347.
47. Lee J, Suh C, Park YH et al. Extranodal natural killer T-cell lymphoma, nasaltype: a prognostic model from a retrospective multicenter study. J Clin Oncol 2006; 24: 612-618.